A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Status:
Completed
Trial end date:
2019-12-25
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when
combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.